종근당, 고혈압 신약 'CKD-339' 국내 3상 임상 신청

Chong Kun Dang's advancement of CKD-339 in Phase 3 clinical testing addresses a critical treatment gap for hypertension patients unresponsive to monotherapy. This combination therapy approach expands treatment options in a major disease category, positioning the candidate for market entry if efficacy and safety are confirmed within the 36-month trial window. The regulatory milestone signals the company's commitment to commercializing innovative hypertension solutions.